The pharmaceutical industry is at an inflection point, where ground-breaking innovation must be translated into transformational value for patients, healthcare professionals and society.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh